[Edaily] C&R Research and Pharos iBio: Advancing as Key Partners in AI-Driven Drug Development
C&R Research has signed a contract to conduct a Phase 1 clinical trial for ‘PHI-501’, an investigational drug being developed by Pharos iBio, a company specializing in AI-driven innovative drug discovery.
‘PHI-501’ is a novel drug candidate identified and optimized using ‘Chemiverse’, Pharos iBio’s AI-powered drug discovery platform. In preclinical studies, it demonstrated excellent therapeutic efficacy in malignant melanoma and refractory colorectal cancer, conditions with limited treatment options.
C&R Research will comprehensively manage the entire clinical trial process, including optimized trial design, data management, statistical analysis, and results reporting, to verify the efficacy and safety of ‘PHI-501’.
As an end-to-end service provider of clinical trials, C&R Research leverages 28 years of experience, advanced IT solutions, and a global network to support and optimize clinical trials for pharmaceutical and biotech companies.
Please check out further details by following the link below.
